Modified oligonucleotide for treating polycystic kidney disease
Patent Information
- Application Number
- HK62026126263
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-11
- Filing Date
- 2026-07-16
- Publication Date
- 2026-09-11
Smart Images

Figure 00000088_0000 
Figure 00000088_0001 
Figure 00000089_0000
Abstract
Description
Abstract This article presents a method for treating polycystic kidney disease, including autosomal dominant polycystic kidney disease, using oligonucleotides modified with miR-17.
Claims
What is claimed is:
1. A method of treating polycystic kidney disease comprising administering to a subject in need thereof a modified oligonucleotide or a pharmaceutically acceptable salt thereof at a dose of 0.5 - 5 mg / kg, 0.5 - 4.5 mg / kg, 0.5 - 4 mg / kg, 0.5 - 3.5 mg / kg, 0.5 - 3 mg / kg, 1 - 5 mg / kg, 1 - 4.5 mg / kg, 1 - 4 mg / kg, 1 - 3.5 mg / kg, or 1 - 3 mg / kg, wherein the modified oligonucleotide has the structure 5’-ASGSCMAFCFUFUMUSAS-3’, wherein nucleosides followed by subscript “M” are 2’-O-methyl nucleosides; nucleosides followed by subscript “F” are 2’-fluoro nucleosides; and nucleosides followed by subscript “S” are S-cEt nucleosides, and wherein each cytosine is a non-methylated cytosine.
2. The method of claim 1, wherein the modified oligonucleotide or a pharmaceutically acceptable salt thereof is administered at a dose of 1 mg / kg, 2 mg / kg, or 3 mg / kg.
3. The method of claim 1 or 2, wherein the pharmaceutically acceptable salt is a sodium salt.
4. A method of treating polycystic kidney disease comprising administering to a subject in need thereof a modified oligonucleotide at a dose of 0.5 - 5 mg / kg, 0.5 - 4.5 mg / kg, 0.5 - 4 mg / kg, 0.5 - 3.5 mg / kg, 0.5 - 3 mg / kg, 1 - 5 mg / kg, 1 - 4.5 mg / kg, 1 - 4 mg / kg, 1 - 3.5 mg / kg, or 1 - 3 mg / kg, wherein the modified oligonucleotide has the structure:or a pharmaceutically acceptable salt thereof.
5. The method of claim 4, wherein the modified oligonucleotide is administered at a dose of 1 mg / kg, 2 mg / kg, or 3 mg / kg.
6. The method of claim 4 or 5, wherein pharmaceutically acceptable salt is a sodium salt.
7. The method of any one of claims 1-6, wherein the modified oligonucleotide is present in a pharmaceutical composition comprising a pharmaceutically acceptable diluent.
8. The method of claim 7, wherein the pharmaceutically acceptable diluent is a sterile aqueous solution.
9. The method of claim 8, wherein the sterile aqueous solution is a saline solution.
10. A method of treating polycystic kidney disease comprising administering to a subject in need thereof a modified oligonucleotide at a dose of 0.5 - 5 mg / kg, 0.5 - 4.5 mg / kg, 0.5 - 4 mg / kg, 0.5 - 3.5 mg / kg, 0.5 - 3 mg / kg, 1 - 5 mg / kg, 1 - 4.5 mg / kg, 1 - 4 mg / kg, 1 - 3.5 mg / kg, or 1 - 3 mg / kg, whereinthe modified oligonucleotide has the structure:
11. The method of claim 10, wherein the modified oligonucleotide is administered at a dose of 1 mg / kg, 2 mg / kg, or 3 mg / kg.
12. The method of claim 10 or 11, wherein the modified oligonucleotide is present in a pharmaceutical composition comprising a pharmaceutically acceptable diluent.
13. The method of claim 12, wherein the pharmaceutically acceptable diluent is a sterile aqueous solution.
14. The method of claim 13, wherein the sterile aqueous solution is a saline solution.
15. The method of any one of claims 1-14, wherein the subject has polycystic kidney disease.
16. The method of any one of claims 1-15, wherein the subject has been diagnosed as having polycystic kidney disease using clinical, histopathologic, and / or genetic criteria.
17. The method of any one of claims 1-16, wherein the polycystic kidney disease is autosomal dominant polycystic kidney disease (ADPKD).
18. The method of claim 17, wherein the subject has Mayo Imaging Classification 1C, ID, or IE of ADPKD.
19. The method of any one of claims 1-18, wherein the subject, prior to administration of the modified oligonucleotide, has an estimated glomerular filtration rate (eGFR) between 30-90 mL / min / 1.73 m2.
20. The method of any one of claims 1-19, wherein the subject, prior to administration of the modified oligonucleotide, was determined to have a decreased level of poly cystin- 1 (PCI) and / or poly cystin-2 (PC2) in the kidney, urine or blood of the subject.
21. The method of any one of claims 1-20, wherein the subj ect has a mutation selected from a mutation in the PKD1 gene or a mutation in the PKD2 gene.
22. The method of any one of claims 1-21, wherein the subject has increased total kidney volume.
23. The method of any one of claims 1-22, wherein the subject has hypertension.
24. The method of any one of claims 1-23, wherein the subject has impaired kidney function.
25. The method of any one of claims 1-24, wherein the method comprises administering the modified oligonucleotide at a dose of 1 mg / kg.
26. The method of any one of claims 1-24, wherein the method comprises administering the modified oligonucleotide at a dose of 2 mg / kg.
27. The method of any one of claims 1-24, wherein the method comprises administering the modified oligonucleotide at a dose of 3 mg / kg.
28. The method of any one of claims 1-27, wherein the method comprises administering the modified oligonucleotide once every 2 weeks.
29. The method of any one of claims 1-28, wherein the method comprises administering the modified oligonucleotide at least 7 times.
30. The method of any one of claims 1-29, wherein the modified oligonucleotide is administered subcutaneously.
31. The method of any one of claims 1-30, wherein the treatment reduces total kidney volume in the subject.
32. The method of any one of claims 1-31, wherein the treatment slows the rate of increase of total kidney volume in the subject.
33. The method of claim 31 or 32, wherein the total kidney volume is height-adjusted total kidney volume (htTKV).
34. The method of any one of claims 1-33, wherein the treatment slows the rate of decline of glomerular fdtration rate in the subject.
35. The method of any one of claims 1-34, wherein the treatment increases glomerular fdtration rate in the subject.
36. The method of claim 34 or 35, wherein the glomerular fdtration rate is estimated glomerular fdtration rate.
37. The method of any one of claims 1-36, wherein the treatment inhibits or slows the increase in the growth of cysts in the kidney and / or liver of the subject.
38. The method of claim 37, wherein the treatment inhibits or slows the increase in total cyst volume, number and / or size distribution.
39. The method of any one of claims 1-38 wherein the treatment: a) improves or slows the rate of decrease of creatinine clearance in the subject; b) reduces or slows the rate of increase of albumin: creatinine ratio in the subject; c) reduces or slows the rate of increase of blood urine nitrogen (BUN) level in the subject; d) reduces or slows the rate of increase of serum creatinine (SCr) level in the subject; e) increases polycystin-1 (PCI) in the urine of the subject; f) increases polycystin-2 (PC2) in the urine of the subject; g) reduces or slows the rate of increase of neutrophil gelatinase-associated lipocalin (NGAL) protein in the urine of the subject; and / or h) reduces or slows the rate of increase of kidney injury molecule- 1 (KIM-1) protein in the urine of the subject.
40. The method of any one of claims 1-39 wherein the administering: a) reduces or slows the rate of increase of monocyte chemoattractant protein- 1 (MCP-1) in the urine of the subject; b) reduces or slows the rate of increase of beta-2 microglobulin (B2M) in the urine of the subject; c) reduces or slows the rate of increase of complement split products C3a and / or Bb in the plasma of the subject;d) reduces or slows the rate of increase of serum insulin-like growth factor binding protein acid labile subunit (IGFALS) in the subject; e) reduces or slows the rate of increase of serum copeptin (CT-proAVP) in the subject; f) reduces or slows the rate of increase of serum N-acetyl-1 -methylhistidine in the subject; and / or g) reduces or slows the rate of increase of acute phase proteins in the subject.
41. The method of any one of claims 1-40, wherein the treatment results in little to no CNS impairment in the subject.
42. The method of claim 41, wherein the treatment results in little to no change in the Scale for the Assessment and Rating of Ataxia (SARA) test score for the subject.
43. The method of one of claims 1-42, comprising: a) measuring height-adjusted total kidney volume (HtTKV) in the subject; b) measuring poly cystin- 1 (PCI) in the urine of the subject; c) measuring poly cystin-2 (PC2) in the urine of the subject; d) measuring blood urea nitrogen (BUN) level in the subject; e) measuring serum creatinine (SCr) level in the subject; f) measuring creatinine clearance in the subject; g) measuring urine albumimcreatinine ratio (UACR) in the subject; h) measuring estimated glomerular fdtration rate (eGFR) in the subject; i) measuring neutrophil gelatinase-associated lipocalin (NGAL) protein in the urine of the subject; j) measuring kidney injury molecule-1 (KIM-1) protein in the urine of the subject; k) measuring monocyte chemoattractant protein-1 (MCP-1) in the urine of the subject; l) measuring beta-2 microglobulin (B2M) in the urine of the subject; m) measuring serum insulin-like growth factor binding protein acid labile subunit (IGFALS) in the subject; n) measuring serum copeptin (CT-proAVP) in the subject; o) measuring serum N-acetyl-1 -methylhistidine in the subject; p) measuring complement split products C3a and / or Bb in the plasma of the subject; and / or q) measuring total cyst volume, number and / or size distribution in the subject; and / or r) measuring SARA test score for the subject.
44. The method of any one of claims 1-43, wherein the subject is a human subject.
45. The method of any one of claims 1-44, which has an acceptable safety and tolerability profde.
46. A modified oligonucleotide or a pharmaceutically acceptable salt thereof for use in treating polycystic kidney disease, wherein the modified oligonucleotide has the structure 5’- ASGSCMAFCFUFUMUSAS-3 ’, wherein nucleosides followed by subscript “M” are 2’-O-methyl nucleosides; nucleosides followed by subscript “F” are 2’-fluoro nucleosides; and nucleosides followed by subscript “S” are S-cEt nucleosides, and wherein each cytosine is a non-methylated cytosine; and wherein the modified oligonucleotide is administered at a dose of 0.5 - 5 mg / kg, 0.5 - 4.5 mg / kg, 0.5 - 4 mg / kg, 0.5 - 3.5 mg / kg, 0.5 - 3 mg / kg, 1 - 5 mg / kg, 1 - 4.5 mg / kg, 1 - 4 mg / kg, 1 - 3.5 mg / kg, or 1 - 3 mg / kg.
47. The modified oligonucleotide for use of claim 46, wherein the modified oligonucleotide is administered at a dose of 1 mg / kg, 2 mg / kg, or 3 mg / kg.
48. The modified oligonucleotide for use of claim 46 or 47, wherein the pharmaceutically acceptable salt is a sodium salt.
49. The modified oligonucleotide for use of any one of claims 46-48, wherein the modified oligonucleotide is present in a pharmaceutical composition comprising a sterile saline solution.
50. The modified oligonucleotide for use of any one of claims 46-49, wherein the polycystic kidney disease is autosomal dominant polycystic kidney disease (ADPKD).
51. The modified oligonucleotide for use of any one of claims 46-50, wherein the modified oligonucleotide is administered once every two weeks.
52. The modified oligonucleotide for use of any one of claims 46-51, wherein the modified oligonucleotide is administered at least seven times.
53. Use of a modified oligonucleotide or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating polycystic kidney disease, wherein the modified oligonucleotide has the structure 5’-ASGSCMAFCFUFUMUSAS-3’, wherein nucleosides followed by subscript “M” are 2’-O-methyl nucleosides; nucleosides followed by subscript “F” are 2’-fluoro nucleosides; and nucleosides followed by subscript “S” are S-cEt nucleosides, and wherein each cytosine is a non-methylated cytosine; wherein the modified oligonucleotide is formulated for administration at a dose of 0.5 - 5 mg / kg, 0.5 - 4.5 mg / kg, 0.5 - 4 mg / kg, 0.5 - 3.5 mg / kg, 0.5 - 3 mg / kg, 1 - 5 mg / kg, 1 - 4.5 mg / kg, 1 - 4 mg / kg, 1 - 3.5 mg / kg, or 1 - 3 mg / kg.
54. The use of claim 53, wherein the modified oligonucleotide is administered at a dose of 1 mg / kg, 2 mg / kg, or 3 mg / kg.
55. The use of claim 53 or 54, wherein the pharmaceutically acceptable salt is a sodium salt.
56. The use of any one of claims 53-55, wherein the modified oligonucleotide is present in a pharmaceutical composition comprising a sterile saline solution.
57. The use of any one of claims 53-56, wherein the polycystic kidney disease is autosomal dominant polycystic kidney disease (ADPKD).
58. The use of any one of claims 53-57, wherein the modified oligonucleotide is administered at least once every two weeks.
59. The use of any one of claims 53-58, wherein the modified oligonucleotide is administered at least seven times.
